Bioprosthetic valve thrombosis in carcinoid heart disease

Kimberly Naden Hollander, Brijen L. Joshi, Brijen Joshi

Research output: Contribution to journalArticle

Abstract

Tricuspid regurgitation in carcinoid syndrome leads to significant morbidity and mortality that may warrant a tricuspid valve replacement. However, for patients with high serotonin levels and known hypercoagulable risks, the optimum timing for surgery and postoperative anticoagulation approaches remain unclear. High serotonin-Triggered hypercoagulability makes prosthetic valves susceptible to thrombosis. Despite appropriate management with a somatostatin analog, some patients continue to have high markers of serotonin that causes platelet aggregation and rapid clot formation. In severely symptomatic patients who require valve surgery, it may not be feasible to postpone surgery until these metabolites are normalized, which may add a substantial risk for postoperative valve thrombosis to an otherwise uneventful procedure. In some, there is a significant need to predict and prevent bioprosthetic valve thrombosis in carcinoid heart disease and to identify best anticoagulation practices across a spectrum of its complex coagulation dynamics and clinical presentation.

Original languageEnglish (US)
Pages (from-to)79-82
Number of pages4
JournalAnnals of Cardiac Anaesthesia
Volume22
Issue number1
DOIs
StatePublished - Jan 1 2019

Fingerprint

Carcinoid Heart Disease
Serotonin
Thrombosis
Tricuspid Valve Insufficiency
Tricuspid Valve
Thrombophilia
Carcinoid Tumor
Somatostatin
Platelet Aggregation
Practice Guidelines
Morbidity
Mortality

Keywords

  • Carcinoid heart disease
  • heart valve prosthesis
  • serotonin
  • thrombosis

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine
  • Anesthesiology and Pain Medicine

Cite this

Bioprosthetic valve thrombosis in carcinoid heart disease. / Hollander, Kimberly Naden; Joshi, Brijen L.; Joshi, Brijen.

In: Annals of Cardiac Anaesthesia, Vol. 22, No. 1, 01.01.2019, p. 79-82.

Research output: Contribution to journalArticle

Hollander, Kimberly Naden ; Joshi, Brijen L. ; Joshi, Brijen. / Bioprosthetic valve thrombosis in carcinoid heart disease. In: Annals of Cardiac Anaesthesia. 2019 ; Vol. 22, No. 1. pp. 79-82.
@article{a68cd0ae7e234a0e86583c761572903b,
title = "Bioprosthetic valve thrombosis in carcinoid heart disease",
abstract = "Tricuspid regurgitation in carcinoid syndrome leads to significant morbidity and mortality that may warrant a tricuspid valve replacement. However, for patients with high serotonin levels and known hypercoagulable risks, the optimum timing for surgery and postoperative anticoagulation approaches remain unclear. High serotonin-Triggered hypercoagulability makes prosthetic valves susceptible to thrombosis. Despite appropriate management with a somatostatin analog, some patients continue to have high markers of serotonin that causes platelet aggregation and rapid clot formation. In severely symptomatic patients who require valve surgery, it may not be feasible to postpone surgery until these metabolites are normalized, which may add a substantial risk for postoperative valve thrombosis to an otherwise uneventful procedure. In some, there is a significant need to predict and prevent bioprosthetic valve thrombosis in carcinoid heart disease and to identify best anticoagulation practices across a spectrum of its complex coagulation dynamics and clinical presentation.",
keywords = "Carcinoid heart disease, heart valve prosthesis, serotonin, thrombosis",
author = "Hollander, {Kimberly Naden} and Joshi, {Brijen L.} and Brijen Joshi",
year = "2019",
month = "1",
day = "1",
doi = "10.4103/aca.ACA_2_18",
language = "English (US)",
volume = "22",
pages = "79--82",
journal = "Annals of Cardiac Anaesthesia",
issn = "0971-9784",
publisher = "Medknow Publications and Media Pvt. Ltd",
number = "1",

}

TY - JOUR

T1 - Bioprosthetic valve thrombosis in carcinoid heart disease

AU - Hollander, Kimberly Naden

AU - Joshi, Brijen L.

AU - Joshi, Brijen

PY - 2019/1/1

Y1 - 2019/1/1

N2 - Tricuspid regurgitation in carcinoid syndrome leads to significant morbidity and mortality that may warrant a tricuspid valve replacement. However, for patients with high serotonin levels and known hypercoagulable risks, the optimum timing for surgery and postoperative anticoagulation approaches remain unclear. High serotonin-Triggered hypercoagulability makes prosthetic valves susceptible to thrombosis. Despite appropriate management with a somatostatin analog, some patients continue to have high markers of serotonin that causes platelet aggregation and rapid clot formation. In severely symptomatic patients who require valve surgery, it may not be feasible to postpone surgery until these metabolites are normalized, which may add a substantial risk for postoperative valve thrombosis to an otherwise uneventful procedure. In some, there is a significant need to predict and prevent bioprosthetic valve thrombosis in carcinoid heart disease and to identify best anticoagulation practices across a spectrum of its complex coagulation dynamics and clinical presentation.

AB - Tricuspid regurgitation in carcinoid syndrome leads to significant morbidity and mortality that may warrant a tricuspid valve replacement. However, for patients with high serotonin levels and known hypercoagulable risks, the optimum timing for surgery and postoperative anticoagulation approaches remain unclear. High serotonin-Triggered hypercoagulability makes prosthetic valves susceptible to thrombosis. Despite appropriate management with a somatostatin analog, some patients continue to have high markers of serotonin that causes platelet aggregation and rapid clot formation. In severely symptomatic patients who require valve surgery, it may not be feasible to postpone surgery until these metabolites are normalized, which may add a substantial risk for postoperative valve thrombosis to an otherwise uneventful procedure. In some, there is a significant need to predict and prevent bioprosthetic valve thrombosis in carcinoid heart disease and to identify best anticoagulation practices across a spectrum of its complex coagulation dynamics and clinical presentation.

KW - Carcinoid heart disease

KW - heart valve prosthesis

KW - serotonin

KW - thrombosis

UR - http://www.scopus.com/inward/record.url?scp=85059974011&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85059974011&partnerID=8YFLogxK

U2 - 10.4103/aca.ACA_2_18

DO - 10.4103/aca.ACA_2_18

M3 - Article

C2 - 30648684

AN - SCOPUS:85059974011

VL - 22

SP - 79

EP - 82

JO - Annals of Cardiac Anaesthesia

JF - Annals of Cardiac Anaesthesia

SN - 0971-9784

IS - 1

ER -